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Left ventricular outflow tract
Myectomy
ObstructionPatientswith hypertrophic cardiomyopathy (HCM) exhibit a variable phenotypewith ventricular hypertrophy as
the cardinal manifestation and left ventricular (LV) outflow tract obstruction (LVOTO) as a key pathophysiologic
determinant. Patients with severe LVOTO usually present with exertional dyspnea, exertional syncope, and heart
failure symptoms, while successful relief of LVOTO by pharmacological or invasive interventions leads to a dra-
matic improvement in clinical status. Propermanagement of obstructiveHCM remains challenging and poses nu-
merous clinical dilemmas. Since the development of surgical myectomy over half a century ago, progress in the
management of LVOTO inHCMhas paralleled technological advances in genetic testing, cardiac imaging, arrhyth-
mic prophylaxis, cardiac surgery and interventional cardiology. These changes have been incorporated in dedi-
cated scientific guidelines on both sides of the Atlantic. However, either the 2011 American guidelines or the
2014 European guidelines remain largely based on expert consensus for lack of recommendations with level of
evidence A regarding any of the treatment options commonly employed in HCM. Consequently, management
of obstructive HCM patients remains largely subjective and dependent on clinical judgment, local expertise,
and patient preference. Following the trend that has emerged for other cardiac diseases amenable to invasive in-
terventions, adequate evaluation and management of obstruction in HCM today requires a multidisciplinary
team capable of optimizing referral, choosing the best available options, minimizing complications and ensuring
state-of-the-art results. The concept of an HCM Heart Team is coming of age. This review aims to provide an up-
date of available pharmacologic and invasive options for themanagement of LVOTO in HCM, either in adulthood
or in childhood, highlighting areas for multidisciplinary integration and future development.
© 2020 Elsevier B.V. All rights reserved.1. Preamble: the clinical burden of obstruction in HCM
Hypertrophic cardiomyopathy (HCM) is a complex cardiovascular
disorder characterized by unexplained non dilated left ventricularar Sciences, University Sapienza
eri, P. Calabrò, et al., Multidi
nal Journal of Cardiology, http(LV) thickening in the absence of other cardiac or systemic diseases jus-
tifying the degree of hypertrophy observed [1]. The morphological, his-
tological, and clinical phenotypes of HCM reflect complex interactions
among a large number of pathophysiologic players triggered by the
causal genetic mutation, generally affecting sarcomere protein genes.
PatientswithHCMexhibit a variable phenotypewith ventricular hyper-
trophy as the cardinal manifestation, myocyte hypertrophy, disarray,
microvascular remodeling and myocardial fibrosis as key pathologicalsciplinary evaluation and management of obstructive hypertrophic
s://doi.org/10.1016/j.ijcard.2020.01.021
Fig. 1. LVOT gradient and obstruction: 50 years of controversies and paradigm shifts.
HCM= hypertrophic cardiomyopathy; LVOT = left ventricular outflow tract.
2 F. Pelliccia et al. / International Journal of Cardiology xxx (xxxx) xxxhallmarks, and impaired ventricular filling and dynamic LV outflow
tract (LVOT) gradients as key pathophysiologic features [1].
LVOT obstruction (LVOTO) in HCM is caused by the systolic anterior
movement (SAM) of elongatedmitral valve leaflets, contacting the sep-
tum at the subaortic level [2]. Patients with severe LVOTO usually pres-
ent with exertional dyspnea or angina, and may experience severe
functional limitation. Relief of obstruction by pharmacological or inva-
sive interventions usually leads to a dramatic improvement in their clin-
ical status and often affords complete relief of limiting symptoms [3].
Because of the heterogeneous manifestations, natural history and
prognosis, tailored management of obstructive HCM remains challeng-
ing and poses numerous clinical dilemmas. Since the development of
surgical myectomy over half a century ago [4], progress in the manage-
ment of LVOTO in HCMhas paralleled technological advances in genetic
testing, cardiac imaging, arrhythmic prophylaxis, cardiac surgery and
interventional cardiology. These changes have been incorporated in
dedicated scientific guidelines for the diagnosis and treatment of the
disease on both sides of the Atlantic. However, neither the
2011AmericanHeart Association/American College of Cardiology guide-
lines [5] nor the 2014 European Society of Cardiology guidelines [6]
could provide any recommendation with a level of evidence A for treat-
ment options commonly employed in HCM. Current recommendations
are based on a bulk ofwell-designed but retrospective studies aswell as
on expert opinions. Consequently, management of LVOTO varies largely
based on local expertise and patient preference. However, adequate
evaluation and management of obstruction in HCM today requires a
multidisciplinary team capable of optimizing referral, choosing the
best available options, minimizing complications and ensuring state-
of-the-art results. Following the trend that has emerged for other car-
diac diseases amenable to invasive interventions, the concept of a
HCM Heart Team is coming of age. This review aims to provide an up-
date of available pharmacologic and invasive options for the manage-
ment of LVOTO in HCM, either in adulthood or in childhood,
highlighting areas for multidisciplinary integration and future
development.
2. Pathophysiology and evaluation of obstruction in HCM
LVOTO has been the source of periodic controversies and paradigm
shifts concerning its genesis and prognostic impact for over 50 years
[2] (Fig. 1). The pathophysiology of HCM was first described in the
'60s by Braunwald et al. [7] andWigle et al. [8] who labeled the disease
as idiopathic hypertrophic subaortic stenosis and muscular subaortic
stenosis, emphasizing the obstructive nature of the disease. In the pre-
echocardiographic era, the presence of an LVOT gradient was consid-
ered a sine qua non of the disease. Following the introduction of Doppler
echocardiography, the true prevalence and clinical spectrum of HCM
were progressively defined: HCM is now known to occur in at least
1:500 of the general population,with about a thirdmanifesting obstruc-
tion in resting conditions and another third only with exercise. Typi-
cally, the LVOT gradient varies with loading conditions and
contractility due to its dynamic nature. Indeed, the gradient can be pro-
voked or augmented by multiple factors, including sympathomimetic
agents, premature ectopic beats, or Valsalva. Thus, exercise echocardi-
ography frequently unmasks latent LVOTO [9]. Therefore,mostHCMpa-
tients have some degree of impedance at the LVOT either at rest or with
provocation.
LVOTO results from the interplay of multiple mechanisms. The key
anatomic determinant is the hypertrophic basal anteroseptal wall,
coupled with a small-sized ventricular cavity narrowing the LVOT. The
functional determinant of obstruction ismitral SAMand the consequent
mitral-septal contact [3]. Initially considered pathognomonic of HCM,
SAM is now recognized in other pathologic conditions altering the ge-
ometry and function of the LV and mitral valve. In HCM, however,
SAM is particularly commondue to the primary abnormalities of themi-
tral valve (enlargement and elongation) and subvalvular apparatusPlease cite this article as: F. Pelliccia, O. Alfieri, P. Calabrò, et al., Multid
cardiomyopathy in 2020: Towa..., International Journal of Cardiology, http(papillary muscle hypertrophy and displacement, abnormal chordal at-
tachments). In addition, evidence now exists that altered flow vectors
generated in the LV cavity alongwith changes in outflow tract geometry
favor the contact between the anterior leaflet of themitral valve and the
hypertrophic septum [10]. These synergistic mechanisms push the leaf-
lets into the outflow tract (‘drag forces’) resulting in LVOTO and loss of
leaflet coaptation, the latter resulting in functional, posteriorly directed
mitral regurgitation [11]. SAM is considered severe if there is septal con-
tact for N30% of the duration of systole.
In a minority of patients (~1%), impedance to flow occurs at mid-
ventricular level and is unrelated to SAM. Mid-ventricular obstructive
HCM is characterized by the presence of a pressure gradient between
the apical and basal portion of the LV, almost creating separate cham-
bers, as a is the result of systolic apposition of the septum and LV free
wall, with the interposition of an anteriorly displaced papillary muscle.
Mid-ventricular obstruction may be associated with an LV apical aneu-
rysm, in the absence of epicardial coronary artery disease.
Doppler echocardiography is the first-line imaging technique to di-
agnose obstructive HCM [5,6], as it documents SAM and allows evalua-
tion of LV morphology and repeated, real-time measures of LVOT
gradients at rest and with Valsalva, thus permitting the hemodynamic
classification of any HCM patient [10] (Supplemental Fig. 1). Although
patients may generate large gradients under non-physiologic or phar-
macological provocation, exercise (stress) echocardiography is consid-
ered the only reliable tool for documenting the presence of latent
LVOTO in physiological conditions [5,6] (Supplemental Table 1). Cardiac
catheterization is rarely required today, unless discordance between
symptoms and non-invasive tests occurs [6]. Besides being a relevant
determinant of outcome [12] (Supplemental Fig. 2), LVOTO is a major
cause of symptoms and should be routinely sought during clinical eval-
uation. North American guidelines advise exercise stress echocardiogra-
phy for identification of latent obstruction in the absence of a
hemodynamically significant (≥50 mmHg) LVOT gradient at rest or
with Valsalva [5]. Conversely, European recommendations warrant ex-
ercise echocardiography in case of symptoms attributable to LVOTO
(e.g. dyspnea, chest pain, exercise limitation, and/or impairedisciplinary evaluation and management of obstructive hypertrophic
s://doi.org/10.1016/j.ijcard.2020.01.021
3F. Pelliccia et al. / International Journal of Cardiology xxx (xxxx) xxxconsciousness). Testing for latent LVOTO is not considered necessary in
asymptomatic patients unless “relevant to lifestyle advice and decisions
on medical treatment” [6].
3. Medical management including novel pharmacologic options
Pharmacological treatment represents the first approach to patients
with obstructive HCM [13] andmaybe effective in controlling LVOTgra-
dients and symptoms. Both North American and European guidelines
have provided specific recommendations [5,6] (Table 1). Beta-blockers
(e.g. atenolol, nadolol, bisoprolol, andmetoprolol) are themost popular
and effective agents employed andmay be titrated based on symptoms,
heart rate response, and blood pressure. Non-dihydropyridine calcium
channel blockers such as verapamil and diltiazemare considered less ef-
fective, although they can be used in patientswho are intolerant or have
contraindications to beta-blockers. Disopyramide, a class IA antiar-
rhythmic agent, can be used in association with beta-blockers or cal-
cium channel blockers to improve symptoms and reduce gradients in
patients with LVOTO by virtue of its negative inotropic effect. Whereas
beta-blockers are most effective on provocable LVOTO, disopyramide
is the most effective agent on resting obstruction. Side effects, such as
QT prolongation and its anticholinergic properties, can limit its use
and impair compliance. Diuretics may be used in patients with pulmo-
nary congestion and should be prescribed at minimal effective doses.
Careful observation is required to avoid hypovolemia, hypotension
and intensification or provocation of LVOTO. In patients with obstruc-
tive HCM and concomitant hypertension or coronary artery disease re-
quiring pharmacological treatment, caution is required with
vasodilators and/or positive inotropic agents and vasodilators (e.g.
phosphor-diesterase inhibitors) because of the risk of exacerbation of
LVOTO [14,15].
Recently, a novel therapeutic approach has emerged based on the
hypothesis that HCM is triggered by a hyper-dynamic state directly
caused by disease-causing sarcomere mutations on the contractile ap-
paratus [16,17]. By selectively decreasing the affinity of myosin for
actin, downstream consequences of sarcomere mutations might be
countered inHCMpatients, including prevention of phenotypedevelop-
ment in the early stages of the disease. A small-molecule allosteric my-
osin inhibitor, mavacamten (MYK-461; Myokardia, San Francisco, CA,
US), has been recently developed to restore physiologic contractility
and energetic balance in HCM by decreasing the adenosine tri-
phosphatase activity of the cardiacmyosin heavy chain. After promising
results obtained in animalmodels,mavacamten has been tested in HCM
patients in the PIONEER-HCM study (A Phase 2 Open-label Pilot Study
Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Car-
diomyopathy and Left Ventricular Outflow Tract Obstruction) [18].
The study enrolled 21 patients aged 18 to 70 years. The primary end-
point was the change in post-exercise peak LVOT gradient at week 12
as compared to baseline. Patients enrolled in the PIONEER-HCM wereTable 1
Pharmacologic indications to treat symptoms associated with HCM based on the 2011
American and 2014 European guidelines.
Drug 2011 ACC/AHA guidelines [5] 2014 ESC guidelines [6]




I - Level of evidence B
IIb - Level of evidence C
I - Level of evidence B




IIa - Level of evidence B
IIa - Level of evidence B
I - Level of evidence B
IIb - Level of evidence C
Diuretics IIb - Level of evidence C IIb - Level of evidence C
ACC = American College of Cardiology; AHA = American Heart Association; ESC =
European Society of Cardiology.
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cardiomyopathy in 2020: Towa..., International Journal of Cardiology, httpdivided into higher dose and lower dose cohorts. In the higher dose co-
hort including 11 patients, mavacamten significantly reduced post-
exercise peak LVOT gradient from 125 mmHg to 19 mmHg (p =
0.002) and improved peak VO2 from 20.7 ml/kg/min to 24.6 ml/kg/
min (p = 0.004) at week 12. Of note, LVOT gradient reduction was
paralleled by a significant reduction in resting LV ejection fraction
(mean change:−15% [CI,−23% to−6%]). Plans are currently underway
for the pivotal EXPLORER-HCM (Clinical Study to Evaluate Mavacamten
in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopa-
thy) study, which would enroll 250 patients and evaluate changes in
peak VO2 and subjective improvement in symptoms based on NYHA
classification as the primary endpoints [19]. Another negative myosin
modulator (CK-274; Cytokinetics, US) is also currently under clinical de-
velopment for HCM patients with LVOTO [20].4. Invasive septal reduction strategies
4.1. Surgical myectomy
Septal reduction therapy should be considered in patients with an
LVOTO gradient greater or equal to 50 mmHg, moderate to severe
symptoms and/or exertional syncope despite maximally tolerated
drug therapy. There are currently two main strategies for septal reduc-
tion: surgical myectomy and alcohol septal ablation (ASA). Surgical
myectomy involves the removal of a small amount (5–10 g) of hyper-
trophic tissue from the basal inter-ventricular septum. Since the first
myectomy was performed in the late 1950s [21], constant develop-
ments and variations have been applied to the procedure. Septal resec-
tion is now often extended circumferentially and distally, to the level of
the papillarymuscles, to avoid residual mid-ventricular obstruction and
to ensure laminar flow through the LVOT area. Unfortunately, extreme
heterogeneity of septal morphology and LV geometry can make septal
myectomy extremely challenging. Careful pre-operative assessment
by means of novel imaging tools (e.g. cardiac magnetic resonance)
nowallows tailoring of the septal excision on an individual basis, includ-
ing apical extension [22]. Indeed, cardiac magnetic resonance provides
reliable assessment of the location, pattern and distribution of LV wall
thickening in the basal septum aiding pre-operative planning and im-
proving surgical outcome [22]. When the obstruction is localized dis-
tally, at the mid-ventricular level, the transaortic approach may prove
challenging. In order to avoid residual obstruction after surgery due to
inadequate length of septal excision, an original application of
cryoenergy can improve the transaortic exposure of the interventricular
septum and thus enable surgeons to perform very distal myectomies
[23]. Alternatively, a combined transaortic and transapical approach
may be used in expert hands. The surgical intervention also allows the
possibility to address concomitant valvular and subvalvular abnormali-
ties in a personalizedmanner, includingmobilization of the right and/or
left fibrous trigones, thus enhancing the dynamic behaviour of the LVOT
[24], and leaflet excision/retraction to reduce mismatch. Furthermore,
there are specific modalities to intervene in cases characterized by se-
vere obstruction in the presence of minimal septal hypertrophy (maxi-
mum thickness ≤ 16 mm) including chordal cutting [25], the edge-to-
edge technique or, in the presence of structural valve disease, prosthetic
valve replacement. When concomitant papillary muscle abnormalities
are present, dissection and reduction of the anomalous papillary appa-
ratus along with chordal cutting and even plication of the mitral valve
are performed as part of the contemporary myectomy operation in
order to completely eliminate LVOT obstruction (Fig. 2). Surgery is the
technique of choice for LVOTO due to congenital discrete subaortic ste-
nosis and in HCM patients with coexistant aortic stenosis [24]. Finally,
concomitant ablation for atrial fibrillation bymeans of Cox-Maze proce-
dure can be performed at time of septal myectomy.With this approach,
an excellent outcome of freedom from atrial fibrillation episodes during
long-term follow-up has been reported [26].sciplinary evaluation and management of obstructive hypertrophic
s://doi.org/10.1016/j.ijcard.2020.01.021
Fig. 2. Secondary chordal cutting in obstructive HCM: effects of secondary chordal cutting
on the geometry and function of the mitral valve apparatus. (A) In patients with
obstructive hypertrophic cardiomyopathy, fibrotic and retracted mitral valve secondary
chordae contribute to displace the body of the anterior leaflet into the left ventricular
outflow tract. (B) Cutting selected abnormal chordae (in combination with a shallow
septal myectomy) moves the mitral valve apparatus and leaflet coaptation point away
from the outflow tract to a more posterior and normal position in the left ventricular
cavity, substantially increasing outflow tract size and decreasing mitral valve tenting
area. (C) Isolated septal myectomy (i.e., without associated chordal cutting) does not
alter the anterior displacement of themitral valve apparatus. Ao=aorta; LA= left atrium;
LV = left ventricle. The figure is from Ferrazzi P et al. and with permission [25].
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Three decades after the first myectomy, Sigwart performed the first
non-surgical septal reduction inHCMbypercutaneous intracoronary al-
cohol injection [27]. ASA aims to induce a limited iatrogenic infarction
localized at the basal septum, positioned to coincide with the point of
contact of the anteriormitral valve leaflet during SAM. Local remodeling
and thinning of the septum are effective in abolishing LVOTO. It is a
catheter-based technique that involves the injection of a small amountPlease cite this article as: F. Pelliccia, O. Alfieri, P. Calabrò, et al., Multid
cardiomyopathy in 2020: Towa..., International Journal of Cardiology, httpof desiccated alcohol (1.5–2.5 mL) into a septal perforator [28]. The
evaluation of LVOT geometry, septummorphology, and valve apparatus
as well as coronary anatomy is crucial to predict ASA feasibility. Major
structural anomalies of the LVOT, mitral valve and papillary muscles
must be excluded, as thesewill prevent an optimal results. The anatomy
of coronary circulation is carefully assessed by coronary angiography,
and the correct identification of one or more ‘target’ septal branches is
of paramount importance [27] (Fig. 3). As a rule, the first septal perfora-
tor is initially tested as target vessel for ASA. Following proximal occlu-
sion of the septal branch by balloon to avoid spillover, contrast
echocardiography is used to confirm that the branch supplies the
basal septum including the area of mitral contact. If there is clear mis-
match with such area, or if there is evidence of contrast diffusion to
other areas (e.g. distal septumor right ventricle), another branch is cho-
sen. Alcohol is injected only when contrast echocardiography suggests
optimal placement.
4.3. Patient selection
Selection criteria for ASA are generally based on anatomical features
and increased operative risk advising against surgery. However, the se-
lection process is controversial and largely depends on local expertise
[28] (Supplemental Table 2).No randomized trial has adequately com-
pared the long term effects of ASA versus myectomy and existing com-
parisons are largely based on registries, case studies or meta-analysis of
observational studies. Such a trial appears unfeasible: based on early tri-
als comparing coronary angioplasty versus by-pass, Olivotto et al. pro-
vided an estimate that 34,000 consecutive patients with HCM would
need to be screened, in order to reach the required total of 1200 enrolled
patients (with 600 patients in each group) achieving statistical power
[29].
Based on available evidence, the 2011 North American guidelines
consider septal myectomy as the gold standard technique for septal re-
duction, and advise against performing ASA in the presence of young
age, severe septal thickness (N25–30 mm), mid-ventricular obstruction
and concomitant cardiac disease [5]. ASA is recommended in the el-
derly, in patients with significant comorbidities increasing surgical
risk, or when patients refuse open-heart surgery [5]. European guide-
lines do not give priority to one technique over another, but suggest
an individual assessment by an experienced multidisciplinary team [6].
Numerous studies now exist showing that both surgical myectomy
and ASA provide durable relief of symptoms and reduction of LVOTO
[28] with excellent long-term survival (Supplemental Fig. 3). To date,
several meta-analyses have found ASA to be non-inferior to myectomy
in terms of subsequent functional improvement, short-term and long-
term mortality [30,31]. Most importantly, procedure-related mortality
in experienced centers for both techniques myectomy and ASA approx-
imates 1% [30,31]. Based on such degree of confidence, HCM patients
with Class II symptoms are increasingly referred to expert centers for
earlier septal reduction therapy, particularly when young or in the pres-
ence of high resting LVOT gradients, severe left atrial dilatation and/or
pulmonary hypertension.
Despite the excellent results obtained by referral centers, several ca-
veats should be considered when considering septal reduction therapy
in HCM patients. First and foremost, operative outcomes vary dramati-
cally based on regional experience: low-flow centers may have unac-
ceptable mortality rates, as well as suboptimal long-term results. The
importance of choosing the appropriate team and technique cannot be
overstated. In addition, several technical pitfalls must be considered.
Muscular septal excision with myectomy may damage the conduction
system, leading to a left bundle branch block. Thus, patients with pre-
existent right bundle branch should either receive ASA or should be in-
formed of a high risk of requiring a pacemaker post-operatively [32].
However, pacemaker rates can be almost two times higher in those un-
dergoing ASA than those undergoingmyectomy. Indeed, ASA can cause
a right bundle branch block in up to 50–60% of patients, and it is bestisciplinary evaluation and management of obstructive hypertrophic
s://doi.org/10.1016/j.ijcard.2020.01.021
Fig. 3. Angiographic sequence of alcohol septal ablation. a Baseline angiogram of the left coronary artery with estimated target septal branch (arrow). b Injection of angiographic contrast
media through the lumen of the over-the-wire balloon (arrow). c Occluded septal branch (arrow) after balloon retraction 10 min after last alcohol injection without damage of the left
anterior descending artery.
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nally, concerns persist regarding the very long-term structural and ar-
rhythmogenic potential of the scar generated by ASA, a major reason
why the procedure is usually avoided in children and adolescents. How-
ever, an increased arrhythmic propensity following ASA has not been
observed in the recent literature [32].
In a proportion of patients who have received invasive septal reduc-
tion, LVOTO can recur during follow-up, particularly in patients treated
with ASA. Similar to staged coronary angioplasty, repeat ASA can be eas-
ily performed at the price of an increase in the risk of pacemaker im-
plantation, although surgery is also very effective. A repeat myectomy
is rare in expert hands and is generally due to incomplete elimination
of LVOTO by the initial procedure, often due to failure to extend the re-
section apically towards the mid-ventricle [21,22].
In conclusion, both ASA andmyectomyhave shown excellent results
in experienced hands. However, most patients will not be equally
poised for both procedures when assessed by an experienced clinician.
Pre-operative evaluation is key in selecting the ideal patient for ASA ver-
sus surgical myectomy. In this regard, the formidable possibilities of
contemporary imaging allow tailored pre-operative planning and are
key in optimizing results while reducing complications. The two proce-
dures require extensive knowledge of the disease, and the learning
curve is demanding. Evidence now exists that available expertise may
prove more important than theoretical considerations in choosing the
right technique.5. Approaching obstruction in children with HCM
HCM is a rare condition in childhood, with an estimated prevalence
of 2.8/100,000, and an annual incidence of between 0.24 and 0.47 per
100,000 [33]. Although most cases are caused by autosomal
dominantly-inherited sarcomere protein gene mutations [33], com-
pared to adults, the etiology of HCM in childhood is heterogeneous
and includes malformation syndromes (e.g. Noonan syndrome and re-
lated disorders of the RAS-MAPK pathway); inborn errors of metabo-
lism (e.g. Pompe disease and other storage disorders); mitochondrial
cytopathies; and neuromuscular disorders (e.g. Friedreich ataxia) [34].
Children with inborn errors of metabolism and malformation syn-
dromes in particular frequently present in infancy (below 1 year of
age) with signs and symptoms of congestive cardiac failure caused by
biventricular outflow tract obstruction and have a substantially poorer
prognosis than those presenting later with sarcomeric or non-
syndromic disease [35].Please cite this article as: F. Pelliccia, O. Alfieri, P. Calabrò, et al., Multidi
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with HCM [35], and can cause symptoms of dyspnoea, chest pain, syn-
cope and presyncope, resulting from an acute reduction in cardiac out-
put, myocardial ischemia and elevated LV filling pressures.
Echocardiographic evaluation should include not just documentation
of the gradient at rest and with provocation manoeuvres (e.g. Valsalva)
but also an assessment of the mechanism of obstruction. In children
with RASopathy syndromes in particular, there is frequently a poly-
valvulopathy that can result in mitral valve dysplasia and accessory at-
tachments from the papillarymuscles to the base of the ventricular sep-
tum and/or the underside of the anterior mitral valve leaflet,
contributing to the presence of complex LVOTO andmitral regurgitation
[36]. Exercise stress echocardiography has also been shown to be feasi-
ble in children with HCM in the assessment of provocable LVOTO [37],
which may be present in up to 50–60% of symptomatic individuals
without a resting LVOT gradient.
The management of LVOTO in children is primarily directed at re-
lieving symptoms, and treatment of asymptomatic children with ob-
structive HCM remains controversial. While there are no prospective
data on the long-term effects of treatment of LVOTO in children, some
retrospective studies have suggested a survival benefit with pharmaco-
logical and/or surgical therapies [38]. In some centers, treatment of rest-
ing LVOT gradients N75–90 mmHg regardless of symptoms is
recommended [34].
Beta-blockers are the initial drug of choice in the treatment of symp-
tomatic LVOTO in children with HCM. The agents most commonly used
include propranolol, atenolol, bisoprolol and metoprolol titrated to
symptoms [34]. When symptoms persist despite adequate beta-
blockade, the addition of disopyramide (dose 6–20 mg/kg/day) can re-
sult in a reduction on the LVOT gradient and improvement in symptoms
[39]. Calcium channel blockers such as verapamil and diltiazem can also
be considered as alternative or additional agents and result in improved
LV relaxation and symptomatic improvement in obstructive HCM; they
should be initiated with caution, usually in an in-patient setting, in chil-
dren with resting LVOTO, as they can sometimes precipitate acute he-
modynamic decompensation [34].
For children with obstructive HCM who remain symptomatic de-
spite maximal pharmacological therapy, or where there is evidence of
a fixed obstructive component (e.g. due to accessory mitral valve
chordal attachments or discrete subaortic membrane with significant
contribution to the LVOT gradient), surgical myectomy can result in sig-
nificant symptomatic improvement together with reduction in degree
of mitral regurgitation and left atrial size [38]. In expert centers, compli-
cation rates (including atrioventricular block, iatrogenic ventricularsciplinary evaluation and management of obstructive hypertrophic
s://doi.org/10.1016/j.ijcard.2020.01.021
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mortality rates generally b2% [38].
Dual chamber pacing has been reported to improve symptoms in
children with HCM and LVOTO, but faster heart rates and shorter
atrio-ventricular conduction velocities compared to adults make opti-
mal programming problematic [40]. In addition, lead and device-
related complications (including infective endocarditis) are relatively
common in the paediatric age group [40]. Therefore, pacemaker treat-
ment for symptomatic LVOTO in children with HCM is limited to those
individuals who are undergoing implantation of an implantable
cardioverter-defibrillator or in the very rare cases where a myectomy
is not possible. Other interventional procedures, such as alcohol septal
ablation, or radiofrequency ablation of the ventricular septum [41], are
currently experimental and should not be used outside the research
setting.
Historical observational studies have suggested that surgical
myectomy may improve survival and reduce the risk of sudden death
in children with obstructive HCM [38], but there are no prospective,
controlled data to confirm this. A recent meta-analysis [42] identified
6 studies assessing LVOTO as a potential risk factor for mortality in chil-
dren with HCM (2 for sudden cardiac death and 4 for all-cause cardio-
vascular death) but only one reported a significant association.
Furthermore, two recent retrospective studies evaluating sudden car-
diac death risk in children and adolescents with HCM suggested an in-
verse relationship between sudden death risk and left ventricular
outflow tract gradient [43,44] The role of LVOTO in risk stratification
in childhood HCM, therefore, remains uncertain and requires further
investigation.
6. The need for a personalized approach and the ‘HCM Heart Team’
The choice of septal reduction therapy should always be based on in-
dividual patient's characteristics, following a multifactorial approach.
ASA remains controversial in children and young adults because of the
lack of long-term data [45].Moreover, this strategymay be less effective
in patients with severe hypertrophy and/or extensive septal scar, due to
the intrinsic limitation of alcohol, and troublesome in case ofmild septal
hypertrophy, due to the risk of septal perforation. The ultimate decision
for the strategy to adopt should always take into account patient prefer-
ence [6]. Thereby, a shared decision-making approach is always to be
preferred, discussing risks and benefits of each treatment strategy,
matching clinical and procedural aspects with the needs and prefer-
ences of the individual patient. For this purpose, it is crucial that the de-
cisional process is carried out with a multi-disciplinary approach by an
experienced teamworking in a dedicated cardiomyopathy center of ex-
cellence. The concept of ‘heart team’, ideally including clinical and inter-
ventional cardiologists, and cardiac surgeons has shown to improve
discussion and decision-making between interventional versus surgical
approach in both coronary artery and valvular heart disease. Following
the same formula, in HCM patients management, a ‘Cardiomyopathy
Team’ should be excellent in analyzing and interpreting diagnostic
tests and contextualizing them in the clinical status of the patient, crit-
ically appraising theneed for a septal reduction intervention, and the in-
dividual benefit-risk ratio with either ASA or myectomy [46]. This team
should be at the least be composed by a clinical cardiologist, an inter-
ventional cardiologist and a cardiac surgeon with recognized experi-
ence in HCM. Implementing the strategical role of cardiomyopathy
teams working in experienced centers is a critical step in the manage-
ment of this population, as the results of both percutaneous and surgical
septal reduction strategy are largely dependent on the experience of the
operators/institutions [47]. In the case of myectomy, alarming data sug-
gest that the real-world mortality rate for the procedure approximates
4–16% [47]. Similarly, in the case of for ASA best results are proven to
be achieved only by highly-experienced operators [48]. Accordingly,
the American guidelines for HCM strictly recommend that all invasive
SRT procedures should be performed by experienced operators in thePlease cite this article as: F. Pelliccia, O. Alfieri, P. Calabrò, et al., Multid
cardiomyopathy in 2020: Towa..., International Journal of Cardiology, httpcontext of a comprehensive HCM clinical program, aiming at minimiz-
ing the rate of death and major complications at b1% and b 3% respec-
tively for isolated septal myectomy [5].
7. Future perspectives
Pharmacological options in patients with HCM have not evolved in
the last decades from the basic objectives of relief of symptoms and im-
provement in functional capacity. Currently, two myosin inhibitors are
being developed for clinical use in symptomatic obstructive HCM with
a Phase 3 randomized controlled trial. To date, however, no drug ther-
apy has yet been shown to prolong survival or reduce the risk of sudden
cardiac death. The development of novel pharmacological strategies
that are capable of altering the natural history of this disease has been
recognized by the National Heart Lung and Blood Institute as an
unmet need and a research priority [49].
To date, judicious use of the available pharmacological armamentar-
iummay already provide sufficient control of themost common clinical
manifestations and complications related to LVOTO, allowing normal
longevity in the majority of male and female patients with HCM [50].
Serial assessment and early identification of disease progression are
key for a timely implementation of available therapies. As regards inter-
ventional techniques, both surgical myectomy and ASA techniques will
continue to exist and improve. Optimizing efficacywhile reducing pace-
maker dependency and improving long-term survival is the obvious ul-
timate goal. The two procedures should be viewed as complementary
rather than competing treatments, enriching the therapeutic armamen-
tarium for HCM patients.
HCM is transitioning into an exciting phase of a pharmacologic dis-
covery and increasing availability of safe and effective invasive inter-
vention for LVOTO. While many of these therapies hold significant
promise to constantly improve the standards of treatment for HCM pa-
tients, significant gaps in knowledge remain in order to radically ad-
dress the molecular basis and natural history of the disease. This
target should set a common agenda for physicians and basic scientist
alike.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.01.021.
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